A Phase II Evaluation of Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum and Paclitaxel-Resistant Ovarian or Primary Peritoneal Cancer

Trial ID # NCT00023907
Phase II
Drug Class Chemotherapy
Drug Name Paclitaxel
Alternate Drug Names Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL
Drugs in Trial Paclitaxel
Eligible Participant

Platinum resistant or refractory ovarian cancer (after first-line platinum-based chemotherapy)

Patients Enrolled


Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, DCR, DoR, evaluated per RECIST


Weekly paclitaxel:
ORR: 20.9% (2CR, 8 PR, n=48)
DCR: 45.8% (2CR, 8PR, 22SD, n=48)
DoR: 3.6 months

Clinically Significant Adverse Events

Serious AE;
Grade 3-4 AE:
25% neurotoxicity, mostly low grade


Weekly paclitaxel shows promising activity in Pt-R and Pt-Rf patients


Markmann M et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol (2006) 101(3): 436-40

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.